Six New Milestones on Our Global Journey
Venus Remedies secured 6 new Marketing Authorizations across Africa and Latin America, expanding its presence in oncology, anti-infective and critical-care therapies
September marked another significant chapter in Venus Remedies’ international growth story, with six new Marketing Authorizations (MAs) secured across key markets in Africa and Latin America. Covering oncology, anti-infective, and critical-care therapies, these approvals strengthen our global footprint and expand access to quality pharmaceutical therapies across diverse international markets.
Strengthening Our Presence in Africa
Out of six, four market authorizations came from African markets. In Ethiopia, Venus received approvals for Etoposide 100 mg/5 ml and Methotrexate 50 mg/2 ml, strengthening our oncology portfolio in the country.
In Senegal, Marketing Authorization was received for Imipenem and Cilastatin 500 mg, adding to our anti-infective presence in the region. Another approval came from the Central African Republic for Paracetamol Infusion 100 ml, expanding the reach of our critical-care portfolio.
Together, these approvals reflect Venus's steady progress across diverse African markets.
Expanding Our Footprint in Latin America
Our progress in Latin America was marked by two new approvals from Chile. The Marketing Authorizations for Fluorouracil 500MG/10ML and Meropenem 1 g add to our growing international portfolio, spanning oncology and anti-infective therapies.
These authorizations strengthen our regulatory footprint in Latin America and support our continued efforts to make quality healthcare accessible worldwide.
Moving Forward in Our Global Journey
Every Marketing Authorization is backed by extensive work across functions, from regulatory submissions and documentation to manufacturing, quality, and international business.
Commenting on these milestones, Ms. Aditi K Chaudhary, President, International Business, Venus Remedies Limited, said:
“Receiving six new Marketing Authorizations across Africa and Latin America marks another meaningful step in Venus Remedies’ global journey. These approvals across oncology, anti-infective, and critical-care therapies reflect our continued focus on regulatory excellence and expanding access to quality medicines in international markets.”
Together, these six approvals represent the collective efforts of teams working towards a common goal: To build a meaningful presence in 100 countries — anchored in enduring partnerships, injectable leadership, and brand credibility.
